Overview

Tesamorelin is a 44-amino acid peptide that acts as a potent GHRH agonist. The addition of its unique N-terminal modification significantly protects the peptide from rapid degradation by dipeptidyl peptidase-4 (DPP-4). This extended half-life allows researchers to evaluate sustained somatotropic signaling and its distinct downstream effects on lipolysis and insulin-like growth factor 1 (IGF-1) secretion.

Click to view CoA Information

Key Research Effects & Mechanisms

• Targeted Visceral Adipose Tissue (VAT) Reduction: Unlike standard GHRH analogs, Tesamorelin is highly evaluated for its specific impact on visceral adiposity (deep abdominal fat surrounding organs). Research models demonstrate its capacity to drive intense lipolysis within these stubborn fat depots by optimizing growth hormone pulsatility.

• Upregulation of Endogenous Growth Hormone: By binding selectively to GHRH receptors on pituitary somatotropes, Tesamorelin triggers a natural, regulated secretion of growth hormone. This allows for the study of body composition modification without the cellular desensitization often caused by exogenous growth hormone.

• Improvement in Metabolic and Lipid Profiles: Independent studies show that exposure to Tesamorelin frequently correlates with improvements in lipid biomarkers, including reductions in triglycerides, non-HDL cholesterol, and overall total cholesterol levels.

• Hepatic Fat and Fibrosis Modulation: Emerging branches of endocrine research focus on Tesamorelin’s potential to reduce ectopic fat accumulation in the liver. Studies track its influence on mitigating non-alcoholic fatty liver pathways and downstream tissue fibrosis

Disclaimer: This product is for research purposes only. It is not intended for direct human consumption.